Evidence map›Paper›PMID 37809084›Full record

ArticleFrontiers in immunology2023

Non-classical HLA-E restricted CMV 15-mer peptides are recognized by adaptive NK cells and induce memory responses.

Nerea Martín Almazán, Benedetta Maria Sala, Tatyana Sandalova, Yizhe Sun, Tom Resink, Frank Cichocki, Cecilia Söderberg-Nauclér, Jeffrey S Miller, Adnane Achour, Dhifaf Sarhan

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. The role of DAP12 in immune-related inflammatory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Does human cytomegalovirus provide a novel therapeutic target for patients with glioblastoma?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Nerea Martín AlmazánDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institute, Stockholm, Sweden.
Benedetta Maria SalaScience for Life Laboratory, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Tatyana SandalovaScience for Life Laboratory, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Yizhe SunDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institute, Stockholm, Sweden.
Tom ResinkScience for Life Laboratory, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Frank CichockiDivision of Hematology, Oncology and Transplantation, University of Minnesota Masonic Cancer Center, Minneapolis, MN, United States.
Cecilia Söderberg-NauclérDepartment of Medicine, Microbial Pathogenesis Unit, Karolinska Institute, Stockholm, Sweden.
Jeffrey S MillerDivision of Hematology, Oncology and Transplantation, University of Minnesota Masonic Cancer Center, Minneapolis, MN, United States.
Adnane AchourScience for Life Laboratory, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Dhifaf SarhanDepartment of Laboratory Medicine, Division of Pathology, Karolinska Institute, Stockholm, Sweden.
Karolinska University Hospital · SEKarolinska Institutet · SEUniversity of Minnesota Medical Center · USUniversity of Turku · FI

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FELICES, MARTIN · 2005 to 2025
$38.2M
Viral priming and targeting NK cells against solid tumor malignanciesR35CA197292 · NCI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2021
$6.2M
NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS R35 CA197292
6 · The paper itself

Abstract

Introduction: Human cytomegalovirus (HCMV) reactivation causes complications in immunocompromised patients after hematopoietic stem cell transplantation (HSCT), significantly increasing morbidity and mortality. Adaptive Natural Killer (aNK) cells undergo a persistent reconfiguration in response to HCMV reactivation; however, the exact role of aNK cell memory in HCMV surveillance remains elusive. Methods: We employed mass spectrometry and computational prediction approaches to identify HLA-E-restricted HCMV peptides that can elucidate aNK cell responses. We also used the K562 cell line transfected with HLA-E0*0103 for specific peptide binding and blocking assays. Subsequently, NK cells were cocultured with dendritic cells (DCs) loaded with each of the identified peptides to examine aNK and conventional (c)NK cell responses. Results: Here, we discovered three unconventional HLA-E-restricted 15-mer peptides (SEVENVSVNVHNPTG, TSGSDSDEELVTTER, and DSDEELVTTERKTPR) derived from the HCMV pp65-protein that elicit aNK cell memory responses restricted to HCMV. aNK cells displayed memory responses towards HMCV-infected cells and HCMV-seropositive individuals when primed by DCs loaded with each of these peptides and predicted 9-mer versions. Blocking the interaction between HLA-E and the activation NKG2C receptor but not the inhibitory NKG2A receptor abolished these specific recall responses. Interestingly, compared to the HLA-E complex with the leader peptide VMAPRTLIL, HLA-E complexes formed with each of the three identified peptides significantly changed the surface electrostatic potential to highly negative. Furthermore, these peptides do not comprise the classical HLA-E-restriction motifs. Discussion: These findings suggest a differential binding to NKG2C compared to HLA-E complexes with classical leader peptides that may result in the specific activation of aNK cells. We then designed six nonameric peptides based on the three discovered peptides that could elicit aNK cell memory responses to HCMV necessary for therapeutic inventions. The results provide novel insights into HLA-E-mediated signaling networks that mediate aNK cell recall responses and maximize their reactivity.

Indexed as

Cytomegalovirus InfectionsCytomegalovirusHistocompatibility Antigens Class IHLA-E AntigensHumansKiller Cells, NaturalPeptidesHistocompatibility Antigens Class IHLA-E AntigensPeptidesAdaptive NK cellsdendritic cellsHLA-Ememorypeptides

Identifiers

PMID37809084
PMCPMC10552778
OpenAlexW4386914836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.